Response and resistance to BET bromodomain inhibitors in triple negative breast cancer

Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy(1-3). BET bromodomain inhibitors, which have shown efficacy in several models of cancer(4-6), have not been evaluated in TNBC. These inhibitors displace BET bromodomain pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Shaokun, Lin, Charles Y., He, Housheng Hansen, Witwicki, Robert M., Tabassum, Doris P., Roberts, Justin M., Janiszewska, Michalina, Huh, Sung Jin, Liang, Yi, Ryan, Jeremy, Doherty, Ernest, Mohammed, Hisham, Guo, Hao, Stover, Daniel G., Ekram, Muhammad B., Brown, Jonathan, D'Santos, Clive, Krop, Ian E., Dillon, Deborah, McKeown, Michael, Ott, Christopher, Qi, Jun, Ni, Min, Rao, Prakash K., Duarte, Melissa, Wu, Shwu-Yuan, Chiang, Cheng-Ming, Anders, Lars, Young, Richard A., Winer, Eric, Letai, Antony, Barry, William T., Carroll, Jason S., Long, Henry, Brown, Myles, Liu, X. Shirley, Meyer, Clifford A., Bradner, James E., Polyak, Kornelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854653/
https://www.ncbi.nlm.nih.gov/pubmed/26735014
http://dx.doi.org/10.1038/nature16508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854653/
https://www.ncbi.nlm.nih.gov/pubmed/26735014
http://dx.doi.org/10.1038/nature16508

Ejemplares similares